November 2008  QED at the partnerships conference in Berlin

Visit us at stand 410 at the 7th Annual Partnerships in Clinical Trials Congress and Exhibition at the Estrel Convention Centre in Berlin, 4th-7th November 2008. For more information and to take advantage of preferential QED booking rates, visit: www.ct-partnerships.com/QED

15.08.2008  QED's ISO 9001 certification program

QED has entered into a program which will bring the existing Quality Management System in line with the requirements of BS EN ISO 9001:2008 and achieve certification within the next 9-12 months. Nazira Maruf, Head of Clinical Operations comments: "This will be an important milestone in our company's history. As a global CRO we will be able to demonstrate globally recognized quality standards, which will help us to be even more successful."

01.03.2008  QED becomes first franchise CRO world-wide

QED is very proud to announce its official membership of the International Franchising Association, making it officially the world’s first franchise CRO. Franchising is a proven strategy utilised in over 70 different industries. The model has been adapted and applied for the first time to the CRO industry by QED cementing their innovative and market leading reputation. Whilst QED has been successfully using this strategy for over 5 years, its inclusion as a member of the IFA officially formalises its status as the world’s first franchise CRO (www.franchise.org). QED’s proven success to date implementing this model makes them experts in this field and this formal recognition will help to further build confidence in this strategy as a flexible, high quality and cost effective approach to outsourcing of clinical studies. Thomas Ogorka, Managing Director of QED said “Membership of the International Franchising Association further confirms confidence in the success of the QED model. This recognition supports the high quality and consistent approach that underpins all of QED’s activities. We are delighted that QED has met the rigorous and high standards set out by the IFA”.

www.franchise.org

24.01.2008   Strategic Alliance Agreement with Semler Research Center

QED Clinical Services Ltd (“QED”), a specialist Clinical Research Organisation in the provision of high quality clinical monitoring services, today announced it has entered into a strategic relationship with Semler Research Center Pvt. Ltd (“SRC”), a CRO in India with expertise in bioanalytical / clinical studies and formulation services.

The alliance provides an excellent balance and fit between the established expertise and capabilities of both QED and SRC in their respective regions and markets. SRC’s established presence in India will allow QED to target local markets, whilst offering SRC the access to participation in global and international clinical trials via QED’s proven global outsourcing model.

QED’s ability to successfully deliver multicenter, global clinical trials in all major therapeutic areas and across phase I-IV development will be complimented by SRC’s vast experience in bioanalytical and bioequivalence trials, whilst also providing critical expertise in the successful delivery of clinical trials in India.

Thomas Ogorka, Managing Director of QED said “This alliance supports our strategy to expand our global coverage and service offering to our sponsors and secures a strong partner to extend the QED model into highly important emerging regions. SRC’s outstanding expertise in the conduct of BA / BE Clinical trials as well as Formulation services will also allow us to provide a more diverse service offering to our customers. We are very excited to be taking this first step towards a long-term collaboration with SRC”.

Dr Gopal Muralidharan, President and CEO of SRC said "This relationship allows us to offer a comprehensive range of Clinical Trial services to our global contacts and clients, by leveraging our scientific knowledge, expertise and foundation in India. The SRC board was unanimous in its decision to form the alliance with QED, since it has proven expertise and built a track record in conducting all aspects of Phase II – IV Trials across the globe and we can now expand on this success into the Indian region and market. We are very enthusiastic with the many opportunities to make this alliance a success not only for SRC and QED, but also to our collective sponsors around the globe."

Back to top